Complete Response to PD-1 Inhibitor in Primary Hepatocellular Carcinoma Patients Post-Progression on Bi-Specific Antibody Conjugated CIK Cell Treatment: A Report of Two Cases-Reference-Cited by-同舟云学术

Complete Response to PD-1 Inhibitor in Primary Hepatocellular Carcinoma Patients Post-Progression on Bi-Specific Antibody Conjugated CIK Cell Treatment: A Report of Two Cases

Published:2021-12 Issue: Volume:Volume 14 Page:5447-5453
ISSN:1178-6930
Container-title:OncoTargets and Therapy
language:en
Short-container-title:OTT

Author:

Wu Tong,Zhang Linzhi,Zeng Zhen,Yan Tao,Cheng Jiamin,Miao Xiaojie,Lu Yinying

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Oncology

Reference18 articles.

Programmed Cell Death Protein-1 (PD-1)-Targeted Immunotherapy for Advanced Hepatocellular Carcinoma in Real World

2. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

3. Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma

4. Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib

5. Advances in drug development for hepatocellular carcinoma: clinical trials and potential therapeutic targets

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Role of immunotherapies and stem cell therapy in the management of liver cancer: A comprehensive review;International Immunopharmacology;2024-05

2. Combination treatment of pembrolizumab with DC-CIK cell therapy for Advanced hepatocellular carcinoma: a case report;BioMedicine;2023-08-28

3. Suppression of MUC1-Overexpressing Tumors by a Novel MUC1/CD3 Bispecific Antibody;Antibodies;2023-07-13

4. Application of adoptive cell therapy in hepatocellular carcinoma;Immunology;2023-07-12